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Abstract
Autoimmune destruction of the pancreatic islets in Type 1 diabetes is mediated by both
increased proinflammatory (Teff) and decreased regulatory (Treg) T lymphocytes resulting
in a significant decrease in the Treg:Teff ratio. The non-obese diabetic (NOD) mouse is an
excellent in vivomodel for testing potential therapeutics for attenuating the decrease in the
Treg:Teff ratio and inhibiting disease pathogenesis. Here we show for the first time that a
bioreactor manufactured therapeutic consisting of a complex of miRNA species (denoted
as TA1) can effectively reset the NOD immune system from a proinflammatory to a tolero-
genic state thus preventing or delaying autoimmune diabetes. Treatment of NODmice with
TA1 resulted in a systemic broad-spectrum upregulation of tolerogenic T cell subsets with a
parallel downregulation of Teff subsets yielding a dramatic increase in the Treg:Teff ratio.
Moreover, the murine-derived TA1 was highly effective in the inhibition of allorecognition of
HLA-disparate human PBMC. TA1 demonstrated dose-responsiveness and exhibited
equivalent or better inhibition of allorecognition driven proliferation than etanercept (a solu-
ble TNF receptor). These findings demonstrate that miRNA-based therapeutics can effec-
tively attenuate or arrest autoimmune disease processes and may be of significant utility in
a broad range of autoimmune diseases including Type 1 diabetes.
Introduction
Autoimmune destruction of pancreatic islets in Type 1 Diabetes (T1D) occurs via T-lympho-
cyte (T cell) dependent pathways.[1–3] Elucidation of the role of T cells in T1D has been most
effectively examined in the non-obese diabetic (NOD) mouse model. In the NODmouse, evi-
dence suggests that a deficit in regulatory T cell (Treg) control over diabetogenic T effector
(Teff) cells leads to the development of insulitis and disease.[2–12] Indeed, changes in the
Treg:Teff ratio (i.e., balance) occurring at 3–4 weeks of age initiates disease progression.[2]
Consistent with the murine findings, human studies have demonstrated that T1D Tregs exhibit
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an impaired ability to suppress Teffs.[13] Thus, the emergence of an aggressive diabetogenic
lymphocyte response in NODmice, and likely humans, is dependent upon a change in the
Treg:Teff ratio.
Consequent to the central role of the T cell in the pathogenesis of diabetes, pharmacological
approaches for the prevention/inhibition of T1D have primarily targeted T cells. Importantly,
whether via cytotoxic targeting, Treg expansion, cytokine adsorption and/or supplementation,
monoclonal antibodies, or amelioration of redox-injury, a consistent therapeutic goal has been
to ultimately change the Treg:Teff ratio.[1,14–19] However, these approaches are characterized
by limited windows of therapeutic efficacy, short duration of efficacy and/or significant toxic-
ity. Hence, the development of novel, immunomodulatory therapeutics directly altering T cell
subset differentiation and, ultimately the Treg:Teff ratio, would be of significant clinical utility
in T1D.
Recent studies have demonstrated that microRNAs (miRNA) are key regulators of cellular
processes including the immune response.[20,21] miRNA are short (~22 nucleotides) single-
stranded RNA molecules found in all eukaryotes. It is estimated that ~60% of mammalian
genes are targeted by one or more miRNA.[22,23] Indicative of their evolutionary and func-
tional importance in gene regulation, miRNA are highly conserved between species (e.g.,
mouse and human).[22] While miRNA are most commonly found intracellularly, significant
levels of stable miRNA are also found in the serum of mammals suggesting an important mes-
senger/regulatory role. Over the last few years, the role of miRNA in disease processes has
become an active research area and recent findings suggest that they may be biomarkers, or
possibly mediators, of T1D.[24–26]
However, miRNA regulation of protein expression is complex and the role of a single
miRNA is difficult to assess as it can potentially affect hundreds of genes and, conversely, indi-
vidual genes can be regulated by multiple miRNA.[23] Consequent to this regulatory complex-
ity, most studies have focused on miRNA as disease biomarkers, not as therapeutic agents.[27–
30] From a bioregulatory approach, it is more probable that the differential expression of mul-
tiple miRNA are necessary for initiating a biological response. Hence, it is this ‘pattern of
miRNA expression’ (encompassing increased, decreased and static levels of multiple miRNAs)
that must be mimicked to achieve pharmacologically effective miRNA-based therapeutics.
However, successful implementation of this bioregulatory approach has not previously been
possible.
Surprisingly, cellular bioengineering via polymer grafting may yield an unexpected avenue
by which a miRNA bioregulatory approach can be achieved. We previously demonstrated that
allorecognition of HLA/MHC-disparate donor leukocytes could be abrogated by the covalent
grafting of methoxypolyethylene glycol (mPEG) to the membrane of cells.[31–38] Moreover,
the immunocamouflage of allogeneic cells by the grafted polymer yielded a non-proliferative
tolerogenic/anergic environment, both in vitro and in vivo, that was mediated by soluble fac-
tors.[33,34,36] It was initially hypothesized that altered cytokine expression patterns, charac-
terized by upregulation of tolerogenic (e.g., IL-10) and downregulation of proinflammatory
(e.g., IL-2, IFN-γ, IL-17A, TNF-α, and Il-6) cytokines, mediated this effect.[36] Intriguingly,
the therapeutic component was found to reside almost solely within the miRNA fraction of
conditioned media or plasma. Using a bioreactor approach, a purified miRNA-based cocktail
(denoted as Tolerance Agent 1; TA1) has been reproducibly generated. To experimentally
assess whether TA1 could arrest or delay a T cell-dependent autoimmune disease process, the
NODmouse model of T1D was examined. NOD mice were treated with saline or TA1 and
examined for T cell subset differentiation, Treg:Teff balance, diabetes incidence, and pancreatic
islet morphology.
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Materials and Methods
Bioreactor production of the TA1 miRNA
Production of the TA1 miRNA-based biologic was accomplished using an in vivomurine
(Balb/c, H-2d; and C57Bl/6, H-2b) bioreactor system. Mice were transfused (i.v.) with saline
(control) or mPEG-grafted (20 kDa SCmPEG; 2 mM grafting concentration per 4 x 106 cells/
mL) allogeneic splenocytes as described by Wang et al.[36] At 5 days post transfusion, heparin-
ized whole blood was harvested and centrifuged (1,500g for 10 minutes; 22°C) for collection of
the control or ‘conditioned’ plasma. Naïve and TA1-miRNA was extracted from the control
and conditioned plasma, respectively, using the mirVanaTM PARISTM kit (Cat. No. AM1556,
Ambion, Life Technologies; Grand Island, NY). Following processing, the highly enriched
small RNA fraction containing miRNA was prepared using RNase/DNase free isotonic saline.
To confirm that miRNA was the active component, aliquots of conditioned plasma and TA1
were RNase-treated (50 ng RNase A; 10 minutes at 37°C; Life Technologies) to degrade the
nucleic acid. The in vivo immunomodulatory effects of the naïve-plasma, naïve-miRNA, condi-
tioned-plasma and TA1-miRNA (all ± RNase A treatment) were confirmed in vivo using
immunocompetent Balb/c or C57Bl/6 mice or in vitro using human or murine mixed lympho-
cyte reactions. To partially characterize and quantify the relative abundance the miRNA species
present in the TA1 bioreactor produced preparation, qPCR miRNA microarrays were analyzed
using an Applied Biosystems StepOnePlusTM Real Time PCR System (ThermoFisher Scientific,
Grand Island, NY) and the Mouse Immunopathology miScript miRNA PCR Array (Qiagen,
Frederick, MD). The PCR array profiles the expression of 84 miRNA differentially expressed
during normal and pathological immune responses. It is worth noting that the 84 miRNA
examined are not all inclusive and that other miRNA are likely present and could be of immu-
noregulatory importance. The data shown represent a minimum of 3 biological replicates ana-
lyzed independently by qPCR.
NODmouse study
All murine studies were performed following protocol approval by the University of British
Columbia Animal Care Committee and were done in accordance with the Canadian Council of
Animal Care guidelines. NOD/ShiLtJ mice were obtained from The Jackson Laboratory (Bar
Harbor, ME, USA). To assess the immunomodulatory efficacy of TA1 in autoimmune T1D,
age of onset, incidence, T cell differentiation and pancreatic islet morphology were measured
in naïve female NODmice treated at 7 weeks of age with either saline or TA1 (N15 per
group). Importantly, at 7 weeks of age, the underlying disease process is well underway.[2]
Treatment consisted of 3 intravenous (i.v.) injections (100 μl each) at 2 day intervals of isotonic
saline or TA1. No further interventions were done. Blood and/or urine glucose levels were
determined weekly (One Touch Ultra Glucometer, LifeScan) to indirectly monitor pancreatic
(ß cell) function. NOD mice that had two consecutive blood glucose values of 20 mM were
defined as diabetic.
Upon loss of normoglycemia, or at week 30, mice were sacrificed and the spleen, pancreatic
lymph node, brachial lymph node and peripheral blood were collected as previously described.
[36] Mouse spleens, pancreatic and brachial lymph nodes were dissected and placed into cold
phosphate buffered saline (PBS; 1.9 mMNaH2PO4, 8.1 mM Na2HPO4, and 154 mMNaCl, pH
7.3) containing 0.2% bovine serum albumin (BSA; Sigma Aldrich, St. Louis, MO) for produc-
tion of single cell suspensions suitable for flow cytometric analysis. Residual erythrocytes in the
splenocytes were removed using BD Pharm Lyse™ lysing buffer (BD Biosciences, San Diego,
CA).[36] Pancreatic ß-cell mass and histopathology was determined via quantitative image
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analysis following insulin immunostaining.[39] Insulitis was scored as normal (0), peri-insulitis
(+, ++) and overt insulitis (+++, ++++).
T cell immunophenotyping by flow cytometry
Samples were acquired and analyzed using a FACSCalibur flow cytometer and CellQuest Pro
software (BD Biosciences, San Jose, CA). All antibodies used were obtained from BD-Pharmin-
gen (San Diego, CA) and used per manufacture’s specifications. To best reflect the in situ leu-
kocyte subpopulations mediating the autoimmune disease pathology, no exogenous
stimulation of the isolated cells was done prior to flow cytometric analysis. Consequent to this
decision, subpopulations are somewhat reduced relative to studies in which in vitro stimulation
(e.g., anti-CD3/CD28) is done prior to flow cytometric phenotyping. Cells (1 x 106 cells total)
were washed and resuspended in PBS (0.1% BSA) for flow acquisition. T cells were defined as
CD3+CD4+. Tolerogenic cells populations included: Foxp3+ (Treg), IL-4+, IL-10+, TGF-β+ T
cells, and CD11c+ dendritic cells (DC). In some experiments, the effect of TA1 on CD25+ and
CD69+ regulatory T cells were also determined.[40,41] Teff cell subpopulations included: IL-
2+; IFN-γ+; TNF-β+; CD40+ and IL-17A+ (Th17 cells) populations. For experimental analysis,
the Treg:Teff ratio was defined as the ratio of Foxp3+ to IL-17A+ (i.e., Th17 cells) cell based on
preliminary experiments and the data observed within the study. Hence, Foxp3+ and IL-17A+
(Th17) cells were simultaneously determined using the BD Th17/Treg kit (BD Pharmingen,
San Diego, CA). All other T cell subset markers were determined independently. All tissues
were analyzed on a per mouse basis.
Human mixed lymphocyte reactions
All experiments using human blood cells were done following protocol approval by the Univer-
sity of British Columbia Clinical Research Ethics Board and in accordance with the Declaration
of Helsinki. Following informed written consent, donor whole blood was collected in heparin-
ized Vacutainer1 blood tubes (BD, Franklin Lakes, NJ). Peripheral blood mononuclear cells
(PBMC) were prepared using Ficoll-Paque PREMIUM (GE Healthcare Bio-Sciences Corp, Pis-
cataway, NJ) and two-way mixed lymphocyte reactions (MLR) were done as previously
described.[36] Sample wells were treated with either saline (200 μl) or increasing amounts of
TA1 (0–200 μl). Cell proliferation was assessed via flow cytometry using the CellTrace CFSE
(Carboxyfluorescein diacetate, succinimidyl ester; 2.5 μMCFSE per 2 x 106 PBMC) Cell Prolif-
eration Kit (Invitrogen by Life Technologies–Molecular Probes, Carlsbad, CA).
Statistical Analysis
Data analysis was conducted using SPSS (v12) statistical software (Statistical Products and Ser-
vices Solutions, Chicago, IL, USA). For significance, a minimum p value of<0.05 was used.
When only two means were compared, student-t tests were performed while one-way analysis
of variance (ANOVA) was performed for comparison of three or more means. When signifi-




The tolerogenic environment induced by the polymer-grafted leukocytes was previously
hypothesized to have arisen from differential cytokine expression.[36] However, as shown in
Fig 1A, fractionation of conditioned murine plasma demonstrated that the active tolerogenic
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component did not reside in the cytokine-rich fractions (10–100 kDa) but was solely in
the 10 kDa fraction; i.e., the miRNA fraction. Indeed, as shown, the cytokine-rich fractions
did not confer any immunomodulatory effects in vivo in immunocompetent Balb/c mice at 5
days post treatment. Moreover, the tolerogenic effects of both the tolerized plasma and the
purified TA1-miRNA were persistent to at least 30 days post-TA1 treatment as evidenced by
the maintenance of elevated Treg and IL-10+ lymphocyte populations (Fig 1B and 1C). In
stark contrast, neither plasma obtained from naive mice, nor miRNA purified from naive
plasma, exerted any immunomodulatory effects on Treg or IL-10+ T cell populations. To deter-
mine whether miRNA (or possibly other small RNAs) were the immunomodulatory active
component, tolerized plasma and TA1 were treated with RNase A. As shown in Fig 1B and
1C, treatment of conditioned plasma and TA1 (Δd and Δd’, respectively) with RNase A signifi-
cantly decreased or abolishment their in vivo effects. Conversely, RNase A treatment of naive
plasma and the naïve miRNA preparation (nor direct i.v. injection of RNase A) had no in vitro
or in vivo effect on T cell differentiation. The pattern of TA1-associated miRNA expression was
determined by qPCR (Fig 1D). The putative functions of the identified miRNA (as currently
described in the literature) are provided in the S1 Table. As noted the TA1-mediated immuno-
modulatory effect arises from a complex patter of miRNA expression encompassing increased,
decreased and static levels of multiple miRNA species. This likely reflects the complex miRNA
bioregulatory mechanism necessary to regulate protein expression, cell proliferation and differ-
entiation. It is important to note that, while several species are individually identified, multiple
other miRNA are present (denoted by grey bars) that are marginally changed relative to naive
miRNAs but may still be of significant bioregulatory importance in mediating TA1 activity.
To assess whether TA1 could effectively blunt an 'autoimmune-like' inflammatory event in
vivo, immunologically normal mice were challenged with H-2 disparate allogenic cells. As
shown in Fig 2, transfusion of naïve Balb/c mice with C57Bl/6 splenocytes resulted in a signifi-
cant (>50%; p<0.001) decrease in Tregs with a corresponding increase in Th17 (~10-fold;
p<0.001) cells at 5 days post challenge. However, TA1 pretreatment (5 days) prior to allogenic
splenocytes challenge prevented both the downregulation of Foxp3+ Treg (Fig 2A) and the
upregulation of Th17 (Fig 2B) cells thus maintaining a Treg:Teff ratio characteristic of naïve
mice. Importantly, the immunomodulatory effects of exogenous TA1 on Treg and Teff subsets
was completely abolished by pre-treatment of TA1 with RNase A (Δc and Δd, respectively).
Moreover, the effect of TA1 on regulatory cells in immunocompetent animals was not limited
to Foxp3+ Tregs. As shown in Fig 2C, TA1 induces significant (p<0.001) increases in both
CD25+ and CD69+ T cells. While CD25+ are of obvious importance as regulatory T cells, the
CD69+ cells may be of equal or greater importance as recent studies have demonstrated their
role in the maintenance of immune tolerance by Foxp3+ regulatory T cells.[40,41] While not
shown directly, the Foxp3+ cells were typically both CD69+ and CD279+ (PD1).
Fig 1. Characterization of miRNA as the functional immunomodulatory agent. Panel A: Size fractionation of plasma obtained from saline (white) and
tolerized (black) mice was done to isolate the tolerogenic fraction(s). As shown, for fractions >10 kDa, in vivo immunodulatory activity was lost (Δd) relative to
the complete plasma. In contrast, the <10kDa fraction demonstrated significantly elevated Treg levels (Δd'; p<0.01) relative to complete plasma. Normal Treg
levels for naïve mice are denoted by the shaded grey bar. As shown, saline treatment had no immunomodulatory effect. Splenic Treg cells were assessed 5
days post treatment (N5 per group). Panels B-C: Comparative in vivo effects of plasma or miRNA prepared from saline and tolerized mice on Foxp3+CD4+
(B) and IL-10+CD4+ (C) lymphocytes at 30 days post treatment. Neither complete plasma nor miRNA prepared from saline treated animals exhibited
immunomodulatory activity. In contrast, conditioned plasma and miRNA (TA1) prepared from it, exhibited significant (p<0.001) upregulation of both Treg and
IL-10+ cells which was lost if the plasma or TA1 (Panels B-C; Δd and Δd’, respectively) was treated with RNase A (RA) prior to administration. Direct in vivo
administration of RA to naive mice had no effect. Values shown are the mean and range of5 animals per group. Panel D: Partial characterization of the
tolerogenic TA1-miRNA pattern. miRNA shown represent species with significant variance from the non-tolerogenic (naïve) miRNA preparation (0 value;
grey line). The tolerogenic pattern consists of miRNA that are both increased and decreased in relative abundance. Note that multiple other miRNA species
are relatively unchanged from naive miRNA but may also be of bioregulatory importance in TA1 activity. Data shown represent a minimum of 3 biological
replicates analyzed independently by qPCR.
doi:10.1371/journal.pone.0145179.g001
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Fig 2. TA1 results in a decreased in vivo inflammatory response upon allogeneic cells challenge. In immunologically competent mice (Balb/c), TA1
completely abrogates the inflammatory response to allogeneic (C57Bl/6) splenocytes. Shown are the levels of Treg and Teff (Th17) cell levels in the spleen
of naïve (N), allogeneic challenged (C) and TA1 treated (± RNase A treatment) mice 5 days post treatment. TA1 was administered 24 hours prior to
administration of the allogeneic splenocytes. As noted, the ‘active’ agent of the TA1 preparation on Treg and Teff levels was fully degraded by RNase
treatment (Δc/d, respectively). Dashed lines represents naïve resting levels of Treg or Th17 cells while the solid lines denote the mean Treg and Th17 cells of
control mice 5 days post transfusion of unmodified, viable, allogeneic splenocytes. Data shown is the mean ± SD of a minimum of 8 mice per group. *
Denotes significantly different (p<0.001) from naïve mice. #Denotes significantly different (p<0.001) from TA1 treated mice. Panel C: In vivo effects of saline,
naive miRNA or TA1-miRNA on Foxp3+, CD25+ and CD69+ T cells in the spleen and brachial lymph node. For ease of comparison, the cross-hatched
regions of the TA1 group represent the mean saline values. Cell populations were determined 5 days post treatment with a minimum of 5 animals per
treatment group. (*) Indicates significantly (p<0.001) different from saline group in Panels A-B. In Panel C (#) denotes significantly reduced from sample 1 but
still significantly (p<0.01) elevated relative to saline group.
doi:10.1371/journal.pone.0145179.g002
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NOD T1D age of onset, incidence and islet histology
To experimentally determine if TA1 could be used therapeutically in an autoimmune disease,
female NODmice were treated at 7 weeks of age with saline or TA1. Importantly, 7 weeks is
well beyond the onset of pancreatic islet immune cell infiltration that begins at 3–4 weeks of
age.[2] As shown in Fig 3A, saline treated NODmice exhibited a rapid onset of diabetes with
75% (12 of 16) of the mice becoming diabetic by 19. Subsequent to week 19, no additional mice
became diabetic. In contrast, by week 19 only 13% (2 of 15) of the TA1 treated mice became
diabetic with an additional 4 mice becoming diabetic between weeks 21 and 23 (total diabetic
6/15; 40%). Analysis of the Treg:Teff ratio of the pancreatic lymph node demonstrated that a
low ratio was correlated with the early onset of diabetes while an elevated Treg:Teff ratio was
Fig 3. TA1 administration prevents (p0.01) or delays T1D (p0.01) progression in NODmice, alters the ratio of Treg:Teff cells and improves islet
histology. Panel A:Mice were treated (i.v.) with either saline or TA1 at 7 weeks of age and blood glucose was measured to a maximum of 30 weeks. Shown
are the percentage of animals remaining normoglycemic (left axis). As shown, only 25% of control mice were normoglycemic at week 19 (line a) while 87% of
TA1 remained normal. At 30 weeks, 25% of untreated mice and 60% of TA1-treated mice remained normoglycemic. Conversion to T1D correlated in both
groups with the log Treg:Teff ratio (left axis). TA1 significantly increased the Treg:Teff ratio in all animals (Diabetic and non-diabetic). The Treg:Teff ratio of
normoglycemic saline (●mean 286; range 170–680) and TA1 (mean 255; range 140–1040) treated mice (shade box; right) were similar but significantly
(p<0.001) higher than diabetic mice. Analysis of the Treg:Teff ratio of diabetic and non-diabetic saline and TA1 mice suggests that an inexact threshold level
(box b) in the Treg:Teff ratio may exist for protection against progression to T1D. Also shown are the Treg:Teff ratios for immunocompetent C57Bl/6 and Balb/
c mice (Δ, 91.5; ■, 198; respectively) and the asymptomatic 7 week old NODmice (▲;103). Diabetic tissues were harvested at time of conversion, non-
diabetic tissues were harvested at week 30. Diabetic values are the mean ± SD of 12 saline and 6 TA1 treated NODmice. For diabetic animals (saline and
TA1 treated) the mean age of onset ± SD is shown via both text and horizontal bar. Non-diabetic results are the mean ± SD of 4 saline and 9 TA1 treated
NODmice. Panel B: TA1 inhibits pancreatic islet insulitis as demonstrated by the increased number of normal (b3) and peri-insulitis (b2) islets relative to
control NODmice. Untreated NODmice exhibited virtually no normal islets (either in diabetic or non-diabetic mice) with a heavy preponderance of overt
insulitis (b1). The numbers shown at the top of each column represent the number of individual islets graded per condition from a minimum of 5 animals per
group.
doi:10.1371/journal.pone.0145179.g003
Inhibition of Autoimmune Diabetes in NODMice by miRNA Therapy
PLOS ONE | DOI:10.1371/journal.pone.0145179 December 16, 2015 8 / 19
associated with either a significantly delayed mean age of onset (20.0 ± 2.7 versus 16.8 ± 1.0 for
TA1 and saline treated diabetic mice respectively; p0.01) or absence (p 0.01 for TA1 relative
to saline treatment) of disease (Figs 3A and 4). These findings correlated with a significant
change (p<0.001) in the Treg:Teff ratio occurs between the 7 week old asymptomatic NOD
mouse (ratio of 103) and the diabetic NODmouse (mean ratio of 4.7; i.e., a ~95% reduction) at
time of sacrifice (Fig 4). Of note, 7 week old NODmice have a Treg:Teff ratio virtually identical
to C57Bl/6 mice (91.5) but roughly half that of naive Balb/c (198).
In comparison to saline treated mice, TA1 treatment universally increased (p<0.001) the
Treg:Teff ratio; even in mice that developed T1D. For diabetic TA1-treated mice, an aggregate
Treg:Teff ratio of 70 was observed (still lower than at age 7 weeks). Non-diabetic mice in both
the saline and TA1 groups demonstrated significantly (p<0.001) elevated Treg:Teff ratios
(Figs 3 and 4). For non-diabetic saline and TA1-treated mice the Treg:Teff ratio was signifi-
cantly higher with mean values of 286 (range 170–680) and 255 (range of 140–1040), respec-
tively. These results suggests that the maintenance of normoglycemia in mature NODmice
required a dramatic tolerogenic reorientation of the immune system over that seen in 7 week
old asymptomatic NOD or immunologically competent (e.g., C57Bl/6 and Balb/c) mice. Fur-
ther analysis of the Treg:Teff data observed in diabetic and non-diabetic mice suggests that a
threshold effect may exist.
The aggregate effect of the TA1-mediated changes in the Treg:Teff balance was not only
reflected by the decreased incidence of diabetes (Fig 3A) but also by improved ß-cell islet his-
tology(Fig 3B). As demonstrated in Fig 3B, untreated NODmice (independent of diabetes sta-
tus) exhibited very high levels of insulitis (b1) and peri-insulitis (b2) with few, if any, normal
Fig 4. TA1 treatment results in significantly increased Foxp3+ (Treg) cells while simultaneously decreasing IL-17A+ (Th17) T cells. Shown are the
flow cytometric data for 3 representative animals from the Control Diabetic (Total N = 12) and TA1 Non-Diabetic (Total N = 9) groups presented in Fig 5. The
ratio of Foxp3+ to Il-17A+ Cells (i.e., the Treg:Teff ratio) is shown in the upper right quadrant. A high Treg:Teff ratio (i.e., > ~200) correlated with maintenance
of normoglycemia (Fig 3A). The gating strategy utilized in shown in the left-most panel. To best reflect the in situ leukocyte subpopulations mediating the
autoimmune disease pathology, no exogenous stimulation of the isolated cells was done prior to flow cytometric analysis.
doi:10.1371/journal.pone.0145179.g004
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islets (b3). In stark contrast, TA1 treatment significantly improved islet histology. In the TA1
treated, non-diabetic, mice 43% of islets were graded as normal and only 14% showed overt
insulitis suggesting that ~86% of islets were capable of some degree of insulin secretion. Per-
haps surprisingly, even in the diabetic TA1-treated mice>19% of islets were normal; greater
than twice the number observed in the non-diabetic (~8%) control mice. The effect of TA1 on
inhibiting islet inflammation, thus preserving islet structure and function, was suggestive of a
systemic tolerogenic reset of the NODmouse lymphoid microenvironment.
Lymphoid microenvironment
The effects of TA1-miRNA therapy on the pancreatic (Fig 5) and non-pancreatic (Fig 6) lym-
phoid microenvironments were assessed. As demonstrated in Fig 5A and S1 Fig, the progres-
sion to diabetes in control NOD mice was characterized by significantly elevated levels of most
Teff subsets (IFN-γ+, Th17+, IL-2+, TNF-α+ and CD40+ lymphocytes) in the pancreatic lymph
node. Importantly, to most accurately reflect the in vivo pathology of the control (saline) and
TA1-treated NODmice, flow cytometric analysis of the recovered leukocytes were assessed in
Fig 5. TA1 therapy dramatically alters the expression of multiple pro-inflammatory (A) and tolerogenic/anergic (B) T cell subsets in the pancreatic
lymph node. In addition TA1 favored pro-tolergenic changes in DC (CD11c+) cells (B). Diabetic tissues were harvested at time of conversion; non-diabetic
tissues were harvested at week 30. Diabetic values are the mean ± SD of 12 saline and 6 TA1 treated NODmice. Non-diabetic results are the mean ± SD of 4
saline and 9 TA1 treated NODmice. Representative flow cytometic data are provided in S1 and S2 Figs To best reflect the in situ leukocyte subpopulations
mediating the autoimmune disease pathology, no exogenous stimulation of the isolated cells was done prior to flow cytometric analysis.
doi:10.1371/journal.pone.0145179.g005
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the absence of any in vitro stimulation. Consequent to this decision, subpopulations are some-
what reduced relative to studies in which in vitro stimulation (e.g., anti-CD3/CD28) is done
prior to flow cytometric phenotyping. As shown, TA1 administration dramatically (p<0.01)
blunted the in vivo expansion of Teff subsets in the pancreatic lymph node relative to both the
diabetic or non-diabetic control NOD mice. Interestingly, with regards to the Teff cell subsets
(with the exception of CD40+ cells) no significant differences were noted between the diabetic
and non-diabetic TA1-treated animals. In large part, this lack of obvious differences in the Teff
subset levels between the TA1-diabetic and TA1-non-diabetic groups arose as a consequence
of the very low levels of the pro-inflammatory cells noted in all of the TA1 treated animals
(perhaps arising from the increase in the tolerogenic cell populations; described below).
Fig 6. The systemic immunomodulatory effects of TA1 therapy are further evidenced by the tolerogenic skewing of the immune cell
subpopulations in the spleen and brachial lymph node. Similar to the pancreatic lymph node, the spleen and brachial lymph node show increased
tolerogenic cell populations and decreased proinflammatory cells following TA1 administration at 7 weeks of age. Diabetic tissues were harvested at time of
conversion; non-diabetic tissues were harvested at week 30. Diabetic values are the mean ± SD of 12 saline and 6 TA1 treated NODmice. Non-diabetic
results are the mean ± SD of 4 saline and 9 TA1 treated NODmice. To best reflect the in situ leukocyte subpopulations mediating the autoimmune disease
pathology, no exogenous stimulation of the isolated cells was done prior to flow cytometric analysis.
doi:10.1371/journal.pone.0145179.g006
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The lone exception to broad-spectrum TA1-mediated decrease in effector cells was the
CD40+ subset. While TA1 significantly reduced (by ~60%) CD40+ cells in the diabetic NOD
mice, the level was still highly elevated relative to both (control and TA1-treated) non-diabetic
groups (~17% versus ~2%). Previous studies have shown that anti-CD40L mAbs can block
insulitis if administered before 3 weeks of age suggesting a critical role for CD40.[42,43] In
light of these studies, it is important to note that TA1 was administered at 7 weeks of age and
was still capable of significantly decreasing the CD40+ subpopulation. It is possible that addi-
tional, or earlier, TA1-treatment would further reduce CD40 expression and substantially
reduce the risk of T1D.
Of potentially greater importance, TA1 treatment significantly increased a broad range of
tolerogenic/anergic cells present in the pancreatic lymph node (Fig 5B; S2 Fig). While Treg
(Foxp3+CD4+) cells were increased by TA1 (Figs 4 and 5B), even more dramatic (relative to
the saline treated mice) miRNA-mediated increases were noted in IL-4+, TGF-β+ and IL-10+ T
cells. Secretion of all three of these cytokines are implicated the generation of immunotolerance
and inhibition of diabetes in NODmice.[5,6,44] The effect of TA1 was not limited to lympho-
cyte populations as the miRNA-treated animals also exhibited significant increases in CD11c+
dendritic cells (DC). With regards to the CD11c+ DC, non-diabetic control and TA1 NOD
mice had significantly elevated (p<0.001) levels of these tolerogenic cells relative to the diabetic
mice.
The immunomodulatory effect of TA1 was not localized to the pancreatic lymphoid micro-
environment. Analyses of immune cell subsets present in the spleen and brachial lymph node
of saline and TA1 treated NODmice similarly demonstrated dramatic changes in the Teff (Fig
6A) and tolerogenic (Fig 6B) T cell subsets. As in the pancreas, TA1 significantly decreased
Teff populations while increasing tolerogenic subsets in both diabetic and non-diabetic NOD
mice thus dramatically increasing the Treg:Teff ratio. Moreover, normoglycemic mice exhib-
ited significantly lower levels of the pro-inflammatory Teff cells in both lymphoid tissues. The
systemic reorientation of the immune system would argue for the potential utility of the
TA1-miRNA therapeutic in other autoimmune diseases.
Much like the complex pattern of miRNA that is necessary for modulating the immune
response, a complex interplay of effector and tolerogenic immune cells is also of crucial import
in determining if a NODmouse will develop diabetes. Changes in any number of components
of the diabetogenic immune response, including either Teff or tolerogeneic cell populations,
may enhance or attenuate progression to overt pathology and diabetes. This differential immu-
nological complexity is noted in Figs 4–6 of the saline and TA1 treated NODmice that either
developed or failed to develop diabetes. However, as shown in Table 1, patterns do exist.
Assessing the aggregate ratio of effector (E) to tolerogenic (T) cells in the saline treated animals
(32.7) clearly demonstrates that a highly proinflammatory environment exists in comparison
to the TA1 treated animals (ratio of 3.7). This proinflammatory state arises consequent to both
an increase in effector T cells (aggregate increase of 9.8) coupled with an aggregate decrease
ratio (0.3) of tolerogenic cells in the diabetic mice relative to non-diabetic mice. Moreover, in
trying to elucidate the relative contribution of specific effector cells in disease pathogenesis,
Table 1 clearly demonstrates that Th17+ and CD40+ cells exhibit a significantly greater pres-
ence in diabetic saline treated animals than do Th1 lineages. The efficacy of TA1 in down regu-
lating the proinflammatory state of the pancreatic lymph node can also be seen in Table 1. As
shown, the aggregate ratio (diabetic:non-diabetic) of effector cells drops from 9.8 to 2.6 (saline
and TA1, respectively). Similarly TA1 therapy significantly increased the tolerogenic cell popu-
lations relative to the saline treated animals. However, despite the dramatic decrease in the
proinflammatory populations and increase in tolerogenic cells, TA1 therapy did not completely
prevent T1D, thus reflecting the complexity of disease pathogenesis.
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TA1 efficacy in the human context
While a large number of therapeutic approaches have shown variable degree of success in the
NODmouse, these approaches have not always been found to be effective in the human con-
text.[45] Importantly, miRNA are highly conserved in mammals suggesting a commonality of
regulation.[22] To investigate whether the murine-derived TA1 was efficacious in preventing
immune recognition in the human context, human mixed lymphocyte reactions (MLR) were
performed. As demonstrated in Fig 7A and 7B, the murine TA1 exerted a dose-dependent
decrease in allorecognition using a two-way MLR model. Indeed at the highest tested dosing
(200 μl) of murine-derived TA1, an ~85% reduction in proliferation of human PBMC was
noted. Moreover, TA1 demonstrated efficacy in the human context equivalent to that of eta-
nercept (Enbrel1; a soluble TNF receptor) a drug currently used in the clinical treatment of
autoimmune diseases. As shown in Fig 7C and 7D, TA1 resulted in the dose dependent inhibi-
tion of alloproliferation of both human CD4+ and CD8+ PBMC in a MLR. Indeed, relative to
etanercept, TA1 demonstrated a significantly improved anti-proliferative effect on cytotoxic
CD8+ T cells. Importantly, this effect was not due to cytotoxicity of the human PBMC as the
murine sourced TA1 did not affect PBMC viability as measured by propidium iodide and
7-AAD staining (data not shown).
Discussion
Autoimmune destruction of the insulin producing ß cells in T1D is mediated by a T cell-depen-
dent inflammatory disease process characterized by a decrease in the Treg:Teff ratio. The loss
of immunological balance most commonly arises from both a decrease in protective regulatory
subsets and a concomitant increase in Teff cells. However, current therapeutics exhibit only
moderate success in arresting disease progression, typically target only Teff subsets, are gener-
ally transient in nature and exert unwanted toxicity to other tissues. A superior approach
Table 1. Ratio of Pancreatic Lymph Node Immune Cells of Saline and TA1 treated Mice: Diabetic/Non-
Diabetic Mice. Derived from Fig 5.
Cell Populations Ratio: Diabetic to Non-
Diabetic
Ratio: Saline to TA1
Saline TA1
Effector Cells (E)
IFN-γ+ 2.5 3.7 0.7
Th17+ 24.0 0.9 27.0
TNF-β+ 3.2 5.2 0.6
IL-2+ 3.0 2.3 1.3
CD40+ 16.2 1.1 14.6
Mean Aggregate E 9.8 2.6 3.8
Tolerogenic Cells (T)
Foxp3+ 0.5 0.9 0.6
IL-4+ 0.3 0.5 0.6
IL-10+ 0.1 0.6 0.2
TGF-β+ 0.2 0.4 0.6
CD11c+ 0.2 0.9 0.2
Mean Aggregate T 0.3 0.7 0.4
Mean Ratio E:T 32.7 3.7
doi:10.1371/journal.pone.0145179.t001
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would be to fundamentally alter the underlying disease state by simultaneously increasing Treg
cells while decreasing Teff cells via normal bioregulatory pathways.
Biologics have become a central focus of much of this research. These immunodulatory
approaches include cytokine adsorption (e.g., Etanercept, a soluble TNF-α receptor), exoge-
nous tolerogenic cytokine supplementation, and targeted (typically blocking) monoclonal anti-
bodies.[17–19] However, these approaches do not effectively address the fundamental
bioregulatory pathways within the animal that, in a disease state, continue to decrease the Treg
cell population. Hence, the global effect of these biologics on the Treg:Teff ratio is often mini-
mal. To successfully alter the Treg:Teff ratio requires a more fundamental bioregulatory
approach.
As demonstrated in this study TA1, a miRNA-based therapeutic, directly targets the Treg:
Teff ratio yielding a systemic pro-tolerogeneic state both in vivo (mouse) and in vitro (human
and mouse). In immunocompetent mice, TA1 treatment resulted in an increased Treg:Teff
ratio consequent to the upregulation of regulatory T cell subsets (e.g., Tregs and IL10+) and the
prevention of an inflammatory Teff response upon challenge with allogeneic splenocytes (Figs
Fig 7. TA1 demonstrates 'drug-like' dosing, efficacy and, consequent to evolutionary conservation, is biologically functional across species.
Panels A-B: Treatment of human PBMC with murine-derived TA1 inhibits allorecognition in a human PBMCmixed lymphocyte reaction. The horizontal
dashed line represents the mean value for resting cells while the horizontal grey bar represents the mean ± SEM for the control MLR value. Panels C-D: Both
etanercept and TA1 exhibit dose dependent inhibition of PBMC proliferation. Relative to etanercept, TA1 shows equivalent (CD4+; Panel C) or better (CD8+;
Panel D) inhibition of human PBMC proliferation after 8 and 14 days of culture. (*) denotes significant (p <0.001 or greater) reduction in proliferation relative
to the control MLR. (¢) denotes the concentration used for the in vivomurine normal (Figs 1 and 2) and NOD (Figs 3–6) studies. Data shown represents the
mean ± SEM of 3 experiments.
doi:10.1371/journal.pone.0145179.g007
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1 and 2). This multivalent, broad-spectrum, immunomodulatory effect of TA1 was mediated
by miRNA as shown by the loss of immunomodulatory activity upon RNase A treatment of
either conditioned plasma or the TA1 preparation (Figs 1 and 2). More interestingly, TA1
functioned effectively in vivo in an autoimmune disease model. In NODmice the Treg:Teff
ratio decreases with age, disease progression and overt hyperglycemia (Fig 3A). A low Treg:
Teff ratio was associated with an early onset of diabetes while an elevated Treg:Teff ratios were
associated with either delayed onset or maintenance of normoglycemia.
Of note, Th17 cells were chosen as the Teff surrogate marker consequent to our findings
that these cells were highly expressed in the pancreas of diabetic animals and were virtually
absent in non-diabetic mice (Figs 4 and 5, Table 1). Furthermore, Th17 cells are potent pro-
inflammatory cells and exhibit an inverse relationship to Treg production.[46–49] However,
similar findings are observed if Th1 (IFN-γ+) cells were used as the surrogate for Teff cells. The
Treg:Th1 ratios for non-diabetic and diabetic control NODmice were 35.8 and 7.7, respec-
tively; a 4.6 fold decrease. In contrast, the Treg:Th1 ratios for TA1-treated non-diabetic and
diabetic mice were 147 and 110, respectively; a minimal 1.3 fold change. The observation that
TA1 decreased the Th1 (IFN-γ+) populations to near baseline levels (Fig 5A) in both diabetic
and non-diabetic mice suggests that other Teff subsets (e.g., Th17), or of equal likelihood, a
defect in the regulatory subpopulations (Fig 5B) may be more critical in disease onset and pro-
gression. Indeed, as shown by the lymphoid microenvironment, diabetes is multifactorial and
unlikely to be solely mediated by a single T cell subset.
The effect of TA1 on other cell types may also be of importance. As shown, TA1 upregulated
both CD25+ cells and CD69+ cells in immunocompetent mice in vivo. In diabetic NOD mice,
DC were significantly (p<0.01) upregulated by TA1 relative to saline treated animals. More-
over, in the non-diabetic animals (saline and TA1), DC were greatly elevated (p<0.01) relative
to the diabetic animals and showed no difference between the saline and TA1 treated animals.
Of note, previous studies have implicated the presence of tolerogenic CD11c+ DC in preventing
T1D disease progression in NODmice. [50–52] In aggregate, these data clearly demonstrate
that TA1 significantly reset the pancreatic lymphoid microenvironment towards a non-inflam-
matory state that yielded a significant reduction in disease progression towards overt diabetes.
Also of significance, diabetic mice (both saline and TA1-treated) tended to have significantly
lower levels of all tolerogenic subsets than non-diabetic (control or TA1) mice thus further
exacerbating the decrease in the Treg:Teff ratio.
The potential utility of this immunomodulatory approach is further supported by the timing
of the TA1 administration. As noted, TA1 was administered at 7 weeks of age, well beyond the
optimal window for therapeutic intervention (3–4 weeks of age).[2] Despite the onset of the
disease process, TA1 was still able to significantly altered the kinetics of change in the Treg:Teff
ratio and decrease the overall incidence of T1D. The TA1-mediated increase in the Treg:Teff
ratio arose from the decrease ofmultiple Teff subsets with a corresponding increase inmultiple
regulatory/tolerogenic T cell subsets in lymphoid tissues (Figs 4–6, Table 1). The increase Treg:
Teff ratio was correlated with a reduction of leukocyte infiltration of the pancreatic lymph
nodes (Fig 3B). Finally, and perhaps not too surprisingly due to their evolutionary conserva-
tion, the murine-derived TA1-miRNA was also highly effective in modulating human leuko-
cyte allorecognition in vitro (Fig 7A and 7B). Similar to traditional therapeutic agents, the
TA1-miRNA product demonstrated a dose response curve in in vitro human MLR studies (Fig
7C and 7D).
The miRNA species complexity of TA1 was done purposefully. Despite the inherent reduc-
tionist nature of science and clinical medicine, an increase or decrease of a single miRNA,
while potentially useful as a biomarker, is unlikely to exert a potent therapeutic effect. Indeed,
based on the known biology and promiscuity of individual miRNA species and the genes they
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regulate, ‘patterns of expression’ (encompassing static, increased and decreased levels of multi-
ple miRNA species) may be crucial in the development of effective miRNA-based therapeutics.
It was this functional ‘pattern of miRNA expression’ that we chose to biologically manufacture
in an attempt to achieve maximal immunomodulatory functionality. As demonstrated in both
immunologically normal and NODmice, and in vitro human studies, the relatively complex
TA1 pattern of miRNA expression (Fig 1D) effectively induced a tolerogenic state. From a
drug perspective, it may be useful to think of TA1 as being analogous to clinically used human
intravenous immunoglobulin (IVIG; pooled human IgG prepared from several thousand
donors) in that TA1 is a ‘complex’ preparation consisting of a broad range of miRNA expressed
with variable abundance relative to naïve miRNA.
Can miRNA therapeutics be stable and reproducible pharmacologic agents? In contrast to
highly labile mRNA, miRNA are relatively stable. The TA1 preparation described withstood
repeated freeze-thaw conditions, exhibited dose dependent activity and showed equivalent effi-
cacy with current, clinically used, immunomodulatory drugs (Fig 7). While the direct mecha-
nism(s) and tissue site(s) by which TA1 modulates the immune response are not fully
understood, evidence to date suggests that multiple lymphoid organs, including the thymus,
are targeted by the exogenous miRNA. Analysis of the putative functions (see S1 Table)
described for the miRNA species identified is suggestive of potential cellular mechanisms with
multiple species being implicated in cellular differentiation and proliferation. Indeed, miR-206
expression is inversely correlated with Th17 proliferation.[53] However, as with any 'drug', it is
also important to note that TA1 may also pose potential toxicity issues due to its potent immu-
nomodulatory effect. Indeed, several miRNA identified in Fig 1D have been implicated in, or
more likely as biomarkers of, carcinogenesis. Chronic immunosuppression using conventional
therapeutics is known to lead to increased risk of cancer and an inability to respond appropri-
ately to exogenous pathogens. It is possible, even probable, that a comparable risk exists for
TA1. Hence further attention to these potential TA1 risks, relative to existing immunosuppres-
sive agents, will be necessary.
As demonstrated, the TA1-miRNA systemically reoriented the immune system of normal and
NODmouse towards a tolerogenic state by increasing the Treg:Teff ratio. In NODmice this
increase inhibited insulitis (i.e., improved histology) and T1D incidence. Indeed, as shown, TA1
exerts a broad-spectrum effect: upregulating regulatory subsets while simultaneously downregulat-
ing Teff subsets yielding a significant increase in the Treg:Teff ratio in multiple lymphoid tissues.
Ongoing studies are examining the effect of different dosing regimes, timing of drug administra-
tion (pre- and post onset of disease) and comparing TA1 to current immunosuppressive drugs.
The findings of this study provide significant new insights into the potential utility of miRNA-
based therapeutics to attenuate not only T1D but other autoimmune diseases as well. The same
miRNA-approach may prove valuable in preventing allorejection of donor tissues as demonstrated
by the ability of the TA1-miRNA to inhibit allorecognition in a humanMLRmodel.
Supporting Information
S1 Fig. TA1 therapy decreased multiple Teff cell subpopulations (relative to control mice)
in the pancreatic lymph node of both diabetic and non-diabetic NODmice. Shown are rep-
resentative flow cytometric data for Saline-Diabetic, TA1-Diabetic, Saline-NonDiabetic and
TA1-NonDiabetic mice as presented in Fig 5. The saline-treated control NODmouse group
consisted of 16 animals while the TA1 treated cohort consisted of 15 animals. To best reflect
the in situ leukocyte subpopulations mediating the autoimmune disease pathology, no exoge-
nous stimulation of the isolated cells was done prior to flow cytometric analysis.
(TIF)
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S2 Fig. TA1 therapy increased multiple toloerogenic cell supopulations (relative to control
mice) in the pancreatic lymph node of both diabetic and non-diabetic NODmice. Shown
are representative flow cytometric data for Saline-Diabetic, TA1-Diabetic, Saline-NonDiabetic
and TA1-NonDiabetic mice as presented in Fig 5. The saline-treated control NODmouse
group consisted of 16 animals while the TA1 treated cohort consisted of 15 animals. To best
reflect the in situ leukocyte subpopulations mediating the autoimmune disease pathology, no
exogenous stimulation of the isolated cells was done prior to flow cytometric analysis.
(TIF)




We thank Drs. Dana Kyluik-Price and Geraldine Walsh for their critical evaluation of the man-
uscript. We also wish to thank Ms. Luxi Wang for her supporting efforts in the laboratory.
Author Contributions
Conceived and designed the experiments: MDS MSH DW. Performed the experiments: DW IS
WMT. Analyzed the data: MDS DWMSH IS WMT. Contributed reagents/materials/analysis
tools: MDS MSH. Wrote the paper: MDS MSH DW.
References
1. Roep BO. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure. Diabetologia.
2003; 46: 305–321. PMID: 12687328
2. Anderson MS, Bluestone JA. The NODmouse: a model of immune dysregulation. Annu Rev Immunol.
2005; 23: 447–485. PMID: 15771578
3. Richer MJ, Lavallee DJ, Shanina I, Horwitz MS. Immunomodulation of antigen presenting cells pro-
motes natural regulatory T cells that prevent autoimmune diabetes in NODmice. PLoS One. 2012; 7:
e31153. doi: 10.1371/journal.pone.0031153 PMID: 22355341
4. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, et al. B7/CD28 costimulation is
essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune
diabetes. Immunity. 2000; 12: 431–440. PMID: 10795741
5. Gregori S, Giarratana N, Smiroldo S, Adorini L. Dynamics of pathogenic and suppressor T cells in auto-
immune diabetes development. J Immunol. 2003; 171: 4040–4047. PMID: 14530324
6. You S, Belghith M, Cobbold S, Alyanakian MA, Gouarin C, Barriot S, et al. Autoimmune diabetes onset
results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabe-
tes. 2005; 54: 1415–1422. PMID: 15855328
7. Tritt M, Sgouroudis E, d’Hennezel E, Albanese A, Piccirillo CA. Functional waning of naturally occurring
CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes. 2008; 57: 113–
123. PMID: 17928397
8. Richer MJ, Straka N, Fang D, Shanina I, Horwitz MS. Regulatory T-cells protect from type 1 diabetes
after induction by coxsackievirus infection in the context of transforming growth factor-beta. Diabetes.
2008; 57: 1302–1311. doi: 10.2337/db07-1460 PMID: 18268045
9. D’Alise AM, Auyeung V, Feuerer M, Nishio J, Fontenot J, Benoist C, et al. The defect in T-cell regulation
in NODmice is an effect on the T-cell effectors. Proc Natl Acad Sci U S A. 2008; 105: 19857–19862.
doi: 10.1073/pnas.0810713105 PMID: 19073938
10. Feuerer M, Shen Y, Littman DR, Benoist C, Mathis D. How punctual ablation of regulatory T cells
unleashes an autoimmune lesion within the pancreatic islets. Immunity. 2009; 31: 654–664. doi: 10.
1016/j.immuni.2009.08.023 PMID: 19818653
11. Nishio J, Feuerer M, Wong J, Mathis D, Benoist C. Anti-CD3 therapy permits regulatory T cells to sur-
mount T cell receptor-specified peripheral niche constraints. J Exp Med. 2010; 207: 1879–1889. doi:
10.1084/jem.20100205 PMID: 20679403
Inhibition of Autoimmune Diabetes in NODMice by miRNA Therapy
PLOS ONE | DOI:10.1371/journal.pone.0145179 December 16, 2015 17 / 19
12. Thayer TC, Wilson SB, Mathews CE. Use of nonobese diabetic mice to understand human type 1 dia-
betes. Endocrinol Metab Clin North Am. 2010; 39: 541–561. doi: 10.1016/j.ecl.2010.05.001 PMID:
20723819
13. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4
(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes. 2005; 54: 92–99. PMID: 15616015
14. NoorchashmH, KwokW, Rabinovitch A, Harrison LC. Immunology of IDDM. Diabetologia. 1997; 40
Suppl 3: B50–57. PMID: 9345646
15. Ryan EA, Lakey JR, Rajotte RV, Korbutt GS, Kin T, Imes S, et al. Clinical outcomes and insulin secre-
tion after islet transplantation with the Edmonton protocol. Diabetes. 2001; 50: 710–719. PMID:
11289033
16. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven
patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J
Med. 2000; 343: 230–238. PMID: 10911004
17. Thomas D, Zaccone P, Cooke A. The role of regulatory T cell defects in type I diabetes and the potential
of these cells for therapy. Rev Diabet Stud. 2005; 2: 9–18. PMID: 17491654
18. Luo X, Herold KC, Miller SD. Immunotherapy of type 1 diabetes: where are we and where should we be
going? Immunity. 2010; 32: 488–499. doi: 10.1016/j.immuni.2010.04.002 PMID: 20412759
19. Lin MS, Tse HM, Delmastro MM, Bertera S, Wong CT, Lakomy R, et al. A multivalent vaccine for type 1
diabetes skews T cell subsets to Th2 phenotype in NODmice. Immunol Res. 2011; 50: 213–220. doi:
10.1007/s12026-011-8215-0 PMID: 21717080
20. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 2005; 120: 15–20. PMID: 15652477
21. Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat
Rev Genet. 2007; 8: 93–103. PMID: 17230196
22. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of micro-
RNAs. Genome Res. 2009; 19: 92–105. doi: 10.1101/gr.082701.108 PMID: 18955434
23. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136: 215–233. doi: 10.
1016/j.cell.2009.01.002 PMID: 19167326
24. Wei B, Pei G. microRNAs: critical regulators in Th17 cells and players in diseases. Cell Mol Immunol.
2010; 7: 175–181. doi: 10.1038/cmi.2010.19 PMID: 20364159
25. Guay C, Roggli E, Nesca V, Jacovetti C, Regazzi R. Diabetes mellitus, a microRNA-related disease?
Transl Res. 2011; 157: 253–264. doi: 10.1016/j.trsl.2011.01.009 PMID: 21420036
26. Nielsen LB, Wang C, Sorensen K, Bang-Berthelsen CH, Hansen L, Andersen ML, et al. Circulating lev-
els of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence
that miR-25 associates to residual beta-cell function and glycaemic control during disease progression.
Exp Diabetes Res. 2012; 2012: 896362. doi: 10.1155/2012/896362 PMID: 22829805
27. Bhardwaj A, Singh S, Singh AP. MicroRNA-based Cancer Therapeutics: Big Hope from Small RNAs.
Mol Cell Pharmacol. 2010; 2: 213–219. PMID: 21289871
28. Braicu C, Calin GA, Berindan-Neagoe I. MicroRNAs and Cancer Therapy—from Bystanders to Major
Players. Curr Med Chem. 2013
29. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance
by a liver-specific MicroRNA. Science. 2005; 309: 1577–1581. PMID: 16141076
30. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. The microRNAmiR-34a inhibits prostate
cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011; 17: 211–215. doi: 10.
1038/nm.2284 PMID: 21240262
31. Murad KL, Gosselin EJ, Eaton JW, Scott MD. Stealth cells: prevention of major histocompatibility com-
plex class II-mediated T-cell activation by cell surface modification. Blood. 1999; 94: 2135–2141. PMID:
10477744
32. Chen AM, Scott MD. Current and future applications of immunological attenuation via pegylation of
cells and tissue. BioDrugs. 2001; 15: 833–847. PMID: 11784214
33. Chen AM, Scott MD. Immunocamouflage: prevention of transfusion-induced graft-versus-host disease
via polymer grafting of donor cells. J Biomed Mater Res A. 2003; 67: 626–636. PMID: 14566806
34. Chen AM, Scott MD. Comparative analysis of polymer and linker chemistries on the efficacy of immuno-
camouflage of murine leukocytes. Artif Cells Blood Substit Immobil Biotechnol. 2006; 34: 305–322.
PMID: 16809132
35. Le Y, Scott MD. Immunocamouflage: the biophysical basis of immunoprotection by grafted methoxy-
poly(ethylene glycol) [mpeg]. Acta Biomater. 2010; 6: 2631–2641. doi: 10.1016/j.actbio.2010.01.031
PMID: 20109585
Inhibition of Autoimmune Diabetes in NODMice by miRNA Therapy
PLOS ONE | DOI:10.1371/journal.pone.0145179 December 16, 2015 18 / 19
36. Wang D, ToyofukuWM, Chen AM, Scott MD. Induction of immunotolerance via mPEG grafting to allo-
geneic leukocytes. Biomaterials. 2011; 32: 9494–9503. doi: 10.1016/j.biomaterials.2011.08.061 PMID:
21885118
37. Wang D, ToyofukuWM, Scott MD. The potential utility of methoxypoly(ethylene Glycol)-mediated pre-
vention of rhesus blood group antigen RhD recognition in transfusion medicine. Biomaterials. 2012; 33:
3002–3012. doi: 10.1016/j.biomaterials.2011.12.041 PMID: 22264524
38. Kyluik-Price DL, Li L, Scott MD. Comparative efficacy of blood cell immunocamouflage by membrane
grafting of methoxypoly(ethylene glycol) and polyethyloxazoline. Biomaterials. 2014; 35: 412–422. doi:
10.1016/j.biomaterials.2013.09.016 PMID: 24074839
39. Montana E, Bonner-Weir S, Weir GC. Beta cell mass and growth after syngeneic islet cell transplanta-
tion in normal and streptozocin diabetic C57BL/6 mice. J Clin Invest. 1993; 91: 780–787. PMID:
8450059
40. Cortes JR, Sanchez-Diaz R, Bovolenta ER, Barreiro O, Lasarte S, Matesanz-Marin A, et al. Mainte-
nance of immune tolerance by Foxp3+ regulatory T cells requires CD69 expression. J Autoimmun.
2014; 55: 51–62. doi: 10.1016/j.jaut.2014.05.007 PMID: 24934597
41. Shen E, Zhao K, Wu C, Yang B. The suppressive effect of CD25+Treg cells on Th1 differentiation
requires cell-cell contact partially via TGF-beta production. Cell Biol Int. 2011; 35: 705–712. doi: 10.
1042/CBI20100528 PMID: 21314640
42. Balasa B, Krahl T, Patstone G, Lee J, Tisch R, McDevitt HO, et al. CD40 ligand-CD40 interactions are
necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol. 1997; 159:
4620–4627. PMID: 9379064
43. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998; 16:
111–135. PMID: 9597126
44. Creusot RJ, Chang P, Healey DG, Tcherepanova IY, Nicolette CA, Fathman CG. A short pulse of IL-4
delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes
in NODmice. Mol Ther. 2010; 18: 2112–2120. doi: 10.1038/mt.2010.146 PMID: 20628358
45. Atkinson MA, Leiter EH. The NODmouse model of type 1 diabetes: as good as it gets? Nat Med. 1999;
5: 601–604. PMID: 10371488
46. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature. 2008;
453: 1051–1057. doi: 10.1038/nature07036 PMID: 18563156
47. Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin
Immunol. 2007; 19: 362–371. PMID: 18035554
48. Korn T, Mitsdoerffer M, Croxford AL, Awasthi A, Dardalhon VA, Galileos G, et al. IL-6 controls Th17
immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc
Natl Acad Sci U S A. 2008; 105: 18460–18465. doi: 10.1073/pnas.0809850105 PMID: 19015529
49. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009; 27: 485–
517. doi: 10.1146/annurev.immunol.021908.132710 PMID: 19132915
50. Gaudreau S, Guindi C, Menard M, Besin G, Dupuis G, Amrani A. Granulocyte-macrophage colony-
stimulating factor prevents diabetes development in NODmice by inducing tolerogenic dendritic cells
that sustain the suppressive function of CD4+CD25+ regulatory T cells. J Immunol. 2007; 179: 3638–
3647. PMID: 17785799
51. Kriegel MA, Rathinam C, Flavell RA. Pancreatic islet expression of chemokine CCL2 suppresses auto-
immune diabetes via tolerogenic CD11c+ CD11b+ dendritic cells. Proc Natl Acad Sci U S A. 2012; 109:
3457–3462. doi: 10.1073/pnas.1115308109 PMID: 22328150
52. Yang H, Cheng EY, Sharma VK, LagmanM, Chang C, Song P, et al. Dendritic cells with TGF-beta1
and IL-2 differentiate naive CD4+ T cells into alloantigen-specific and allograft protective Foxp3+ regu-
latory T cells. Transplantation. 2012; 93: 580–588. doi: 10.1097/TP.0b013e318244dd67 PMID:
22270834
53. Tang X, Tian X, Zhang Y, WuW, Tian J, Rui K, et al. Correlation between the frequency of Th17 cell
and the expression of microRNA-206 in patients with dermatomyositis. Clin Dev Immunol. 2013; 2013:
345347. doi: 10.1155/2013/345347 PMID: 24288551
Inhibition of Autoimmune Diabetes in NODMice by miRNA Therapy
PLOS ONE | DOI:10.1371/journal.pone.0145179 December 16, 2015 19 / 19
